<DOC>
	<DOCNO>NCT01071655</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety capecitabine 5-fluorouracil selection , accord polymorphisms TS-3'UTR ERCC1-118 , combine oxaliplatin irinotecan first-line chemotherapy advance colorectal cancer</brief_summary>
	<brief_title>Selecting Treatment Colorectal Cancer : Capecitabine 5-fluorouracil Selection Combined With Oxaliplatin Irinotecan First-line Chemotherapy Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>informed consent sign Histological citological adenocarcinoma confirmation carcinoma colon colorectal metastatic relapse patient adenocarcinoma colon recto , confirm histologically metastatic disease measurable disease ( follow RECIST criterion ) ECOG ≤ 2 old equal 18 year old life expectancy superior 3 month Adequate moderate renal function : renal function ( Creatinine clearance &gt; 30mL/min ) , base Cockroff Gault . Potential fertile woman negative pregnancy test serum urine , 10 day prior first study dose give Use adequate contraceptive method Patients treat previously Bevacizumab Non measurable lesion disease evidence Previous chemotherapy treatment adjuvant neoadjuvant disease ( metastatic ( M0 ) , immunotherapy active/passive advance metastatic disease . It permit adjuvant neoadjuvant treatment finish least 6 month initiation study drug.If patient receive adjuvant treatment previously patient participate disease progression confirm treatment 6 month later Prior radiotherapy allow administered target lesion select study , unless progression say lesion irradiated field document , long treatment conclude least 4 week begin study . Prior surgical treatment disease stage IV allow Functional dependency Previous serious adverse event unexpected fluoropyrimidine treatment /o patient prove deficit dehidropirimidin dehydrogenase ( DPD ) Patients classify `` weak fragile '' Cardiac concomitant present : Symptomatic auriculoventricular arrhythmia history , / cardiac arrhythmia require medication peripheral vascular disease , grade II high . Furthermore , patient myocardial infarction year prior begin treatment study exclude . History another neoplastic disease last five year , exception cure basal cell carcinoma skin cervical carcinoma situ . History indication CNS disease physical examination . History psychiatric disability investigator considers clinically significant , prevents patient grant informed consent interferes compliance take oral medication . Uncontrolled hypertension clinically significant ( i.e . active ) cardiovascular disease : CVA/stoke ( ≤ 6 month prior randomisation ) , myocardial infarction ( ≤ 6 month prior randomisation ) , unstable angina , New York Heart Association ( NYHA , ) Grade II great congestive heart failure , serious cardiac arrhythmia require medication . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome inability take oral medication . Patients subject organ allograft require immunosuppressive treatment . Severe , noncicatrized osseous fracture , wound ulcer Indications hemorrhagic diathesis coagulopathy . Severe , uncontrolled intercurrent infection severe , uncontrolled concomitant disease . Any following laboratory value : 1 . Absolute neutrophil count ( ANC ) &lt; 1.5 x 109/l 2 . Platelet count &lt; 100 x 109/l 3 . Hemoglobin &lt; 10 g/dl ( transfused maintain exceed level ) 4. International Normalized Ratio ( INR ) &gt; 1.5 5 . Total bilirubin &gt; 1.5 time upper limit normal ( ULN ) 6 . ALAT , ASAT &gt; 2.5 x ULN &gt; 5 x ( ULN ) case hepatic metastasis 7 . Alkaline phosphatase &gt; 2.5 x ULN &gt; 5 x ULN case hepatic metastasis &gt; 10 x ULN case osseous metastasis . Patients subject major surgical procedure , open biopsy significant traumatic lesion within 28 day prior begin treatment study foreseen major surgical procedure necessary course study ; fineneedle aspiration within 7 day prior begin treatment study . Current recent use ( within 10 day prior begin treatment study ) oral parenteral anticoagulant complete dos thrombolytic agent . The use low dos warfarin allow , International Normalized Ratio [ INR ] &lt; 1.5 . Daily chronic treatment high dos aspirin ( &gt; 325 mg/day ) nonsteroid antiinflammatory medication ( inhibit platelet function dos use treat chronic inflammatory disease ) . Patients receive drug agent/procedure research , i.e. , participate another clinical trial 4 week prior begin treatment medication study . Pregnancy lactate woman . Woman reproductive potential unless use effective method contraception ( Postmenopausal woman must amenorrheic least 12 month ) . Known hypersensitivity study drug excipients Bevacizumab Chinese hamster ovary cell product recombinant human humanise antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>5FU</keyword>
	<keyword>capecitabine</keyword>
</DOC>